Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines and vaccines across multiple therapeutic areas. The company is known for large-scale R&D, global manufacturing and distribution, and partnerships spanning academia, biotech, and technology providers.
Think of every patient as a unique garden: their genes are the soil, epigenetics is how the soil has been treated over time (fertilizer, pollution, stress), and the microbiome is the mix of plants and microbes living there. This work is about using data and models to understand how all three together affect health and how people respond to medicines, so treatments can be tailored to each person’s “garden” instead of using one-size-fits-all drugs.
Think of today’s big AI models as brilliant general doctors who know a little about everything but aren’t yet safe or precise enough to treat complex, high‑risk patients. This paper is about how to retrain and constrain those general doctors so they can safely become top‑tier specialists in specific medical tasks, like reading scans, summarizing patient records, or supporting treatment decisions.
Think of this as a field guide to all the ways computers can learn from medical and pharma data—like a tireless junior doctor and data analyst rolled into one—to help spot diseases earlier, pick better treatments, and run hospitals and clinical trials more efficiently.